<qa>  What is the main objective of the trial?The main objective of the trial is to determine the efficacy of doxorubicin-loaded anti-EGFR immunoliposomes as first-line therapy in patients with advanced triple Negative, EGFR positive breast cancer. In this proof of concept trial, all patients will have an administration of the doxorubicin-loaded anti-EGFR immunoliposomes anti-EGFR-IL-dox every 28 days, until progression or unacceptable toxicity. 